Survival of cancer is inevitably improved by early detection and diagnosis. Unfortunately, most cancers are currently diagnosed late when the cancer is already well established and may have spread beyond the primary tumour. ValiBIO is developing new cancer diagnostics based on several approaches but particularly on two independent patented technologies, “HyperGenomics^TM” and “Nucleosomics^TM” licensed to the Company by ValiRx plc.

ValiBIO will improve life of cancer patients by developing low cost, rapid, high throughput, non-invasive screening tests for the early detection of cancer and ofr the differential diagnosis and prognosis of cancer to facilitate early, optimal and personalized treatment regimes.

Company Ethics

The Company is committed to conduct its business according to the most rigorous ethical standards. In particular the company will use human samples according to strict ethical agreed procedures and from Biobanks which meet the highest ethical standards.